Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant Bioavailability and Food Effect Study
NCT03682380Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of seltorexant in major depressive disorder (MDD) and Insomnia (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Area Under the Plasma Concentration-Time Curve from Time of Dosing to Last Measurable Concentration at 48 hours and 1 more. Started Oct 2018; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT03682380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682380.